Boston Scientific acquired a re-entry catheter in November 2010 from Israel-based SI Therapies.

The company will also acquire an intraluminal CTO crossing device through its acquisition of Sunnyvale, CA-based ReVascular Therapeutics, which is expected to close this month.

CTO devices permit endovascular treatment in cases that otherwise might require a patient to undergo surgery or lower extremity amputation.

Boston Scientific president and CEO Ray Elliott said these acquisitions demonstrate their continued strategic execution of realigning and strengthening their portfolio in areas with high-growth potential.

"Our Priority Growth Initiatives include peripheral vascular disease, in which a significant number of patients remain undiagnosed or untreated. Addressing these challenges through use of less-invasive devices could greatly improve the care these patients receive," Elliott said.